Logotype for Novolog (Pharm-Up 1966) Ltd

Novolog (NVLG) Q2 2024 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Novolog (Pharm-Up 1966) Ltd

Q2 2024 earnings summary

13 Jun, 2025

Executive summary

  • Revenue for H1 2024 reached ₪1,643.5M, up 11.5% year-over-year, mainly from logistics growth.

  • Q2 2024 revenue was ₪428M, up 3.6% from Q2 2023.

  • Net income for Q2 2024 was ₪13.2M, up 11.4% year-over-year; H1 2024 net income was ₪13.3M, stable year-over-year.

  • Adjusted EBITDA for Q2 2024 was ₪34.8M; H1 2024 Adjusted EBITDA was ₪84.9M, up 3.7% year-over-year.

  • No material negative impact identified from Israel's credit rating downgrade.

Financial highlights

  • Q2 2024 net income: ₪13.2M; H1 2024 net income: ₪13.3M.

  • Q2 2024 gross profit: ₪45.4M, up 4.3% year-over-year; H1 2024 gross profit: ₪169.2M, up 8.6%.

  • Q2 2024 Adjusted EBITDA: ₪34.8M; H1 2024 Adjusted EBITDA: ₪84.9M.

  • Cash position at end of Q2 2024: ₪232.9M.

  • Dividend of ₪15M declared for September 2024.

Outlook and guidance

  • Management is monitoring the Gaza conflict and geopolitical tensions, with no significant adverse effects identified.

  • The company is reviewing long-term strategy and expanding logistics capacity, including a new distribution center.

  • Focus remains on organic growth, strategic acquisitions, and high dividend payouts.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more